Discussions that mention requip

Pain Management board


CLINICAL PHARMACOLOGY

Mechanism of Action and Pharmacodynamics

Persistent activation of central nervous system N-methyl-D-aspartate (NMDA) receptors by the excitatory amino acid glutamate has been hypothesized to contribute to the symptomatology of Alzheimer’s disease. Memantine is postulated to exert its therapeutic effect through its action as a low to moderate affinity uncompetitive (open-channel) NMDA receptor antagonist which binds preferentially to the NMDA receptor-operated cation channels. There is no evidence that memantine prevents or slows neurodegeneration in patients with Alzheimer’s disease.
...............................................................................................................
Nemanda is a NMDA antagonist, so although it was developed as a parkinsons med, obviously the manufacturer reps are out there breaking the law calling on PM docs suggesting the off label use of Nemanda.

This is what got the manufacturer of Neurontin in trouble. The reps can not suggest off label use of meds to docs. Although PM docs are aware of the power of blocking NMDA receptors, the reps have no buisness calling on PM docs.

I'm sure we will see the same type of law suites that have the manufacturer of neurontin tied up. It is legal to use meds for off label purposes, the reps just can't suggest it. Miripex and Requip are also parkinsons meds but the PM docs use it to combat restless leg syndrome brought on by opiate use. I'm sure we will see CP patients on Nemanda soon enough.
Take care, Dave